Division of Infectious Diseases, Department of Medicine, School of Medicine, Johns Hopkins University, Baltimore, Maryland, USA.
MicuRx Pharmaceuticals, Inc., Foster City, California, USA.
Antimicrob Agents Chemother. 2024 Nov 6;68(11):e0135124. doi: 10.1128/aac.01351-24. Epub 2024 Oct 3.
) is an opportunistic pathogen common in patients with lung comorbidities and immunosuppression. There are no FDA-approved treatments, and current treatment has a failure rate exceeding 50%. The intravenous oxaborole MRX-6038 is active against . This study evaluated MRX-5, the oral prodrug, against five isolates in a mouse lung infection model. MRX-5 showed dose-dependent efficacy, with 15 and 45 mg/kg doses comparable to the standard of care, supporting progression to clinical trial.
是一种机会性病原体，常见于肺部合并症和免疫抑制的患者。目前尚无 FDA 批准的治疗方法，且现有治疗方法的失败率超过 50%。静脉注射硼替佐米类药物 MRX-6038 对具有活性。本研究评估了口服前药 MRX-5 在小鼠肺部感染模型中对五种 分离株的疗效。MRX-5 表现出剂量依赖性疗效，15 和 45mg/kg 剂量与标准治疗相当，支持进入临床试验。
